JP2003508059A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003508059A5 JP2003508059A5 JP2001520901A JP2001520901A JP2003508059A5 JP 2003508059 A5 JP2003508059 A5 JP 2003508059A5 JP 2001520901 A JP2001520901 A JP 2001520901A JP 2001520901 A JP2001520901 A JP 2001520901A JP 2003508059 A5 JP2003508059 A5 JP 2003508059A5
- Authority
- JP
- Japan
- Prior art keywords
- serum
- homocysteine
- concentration
- vitamin
- risk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 description 29
- 210000002966 serum Anatomy 0.000 description 26
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 20
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 17
- 108010047320 Pepsinogen A Proteins 0.000 description 15
- 229930003779 Vitamin B12 Natural products 0.000 description 13
- 235000019163 vitamin B12 Nutrition 0.000 description 13
- 239000011715 vitamin B12 Substances 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000003556 assay Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 102000005954 Methylenetetrahydrofolate Reductase (NADPH2) Human genes 0.000 description 4
- 108010030837 Methylenetetrahydrofolate Reductase (NADPH2) Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 102000023732 binding proteins Human genes 0.000 description 4
- 108091008324 binding proteins Proteins 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000004907 gland Anatomy 0.000 description 4
- 206010003694 Atrophy Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 239000012491 analyte Substances 0.000 description 3
- 230000037444 atrophy Effects 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 208000019553 vascular disease Diseases 0.000 description 3
- 208000004300 Atrophic Gastritis Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 208000036495 Gastritis atrophic Diseases 0.000 description 2
- 208000032382 Ischaemic stroke Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 108010066264 gastrin 17 Proteins 0.000 description 2
- GKDWRERMBNGKCZ-RNXBIMIWSA-N gastrin-17 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 GKDWRERMBNGKCZ-RNXBIMIWSA-N 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- CKRJGDYKYQUNIM-UHFFFAOYSA-N 3-fluoro-2,2-dimethylpropanoic acid Chemical compound FCC(C)(C)C(O)=O CKRJGDYKYQUNIM-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000195620 Euglena Species 0.000 description 1
- 241000195619 Euglena gracilis Species 0.000 description 1
- 102400000921 Gastrin Human genes 0.000 description 1
- 208000033892 Hyperhomocysteinemia Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- ZJUKTBDSGOFHSH-WFMPWKQPSA-N S-Adenosylhomocysteine Chemical compound O[C@@H]1[C@H](O)[C@@H](CSCC[C@H](N)C(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZJUKTBDSGOFHSH-WFMPWKQPSA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000001867 cobalamins Chemical class 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000000835 electrochemical detection Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000003225 hyperhomocysteinemia Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 201000011531 vascular cancer Diseases 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 208000002670 vitamin B12 deficiency Diseases 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI19991836 | 1999-08-31 | ||
| FI991836A FI107808B (fi) | 1999-08-31 | 1999-08-31 | Menetelmä verisuoni- sekä syöpäsairaudelle riskialttiin yksilön identifioimiseksi |
| PCT/FI2000/000733 WO2001016356A1 (en) | 1999-08-31 | 2000-08-30 | Method for identifying an individual at risk for vascular and cancer disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003508059A JP2003508059A (ja) | 2003-03-04 |
| JP2003508059A5 true JP2003508059A5 (enExample) | 2007-10-11 |
Family
ID=8555217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001520901A Pending JP2003508059A (ja) | 1999-08-31 | 2000-08-30 | 管疾患及び癌の危険性のある人を同定する方法 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1210452A1 (enExample) |
| JP (1) | JP2003508059A (enExample) |
| CN (1) | CN1158389C (enExample) |
| AU (1) | AU6845600A (enExample) |
| FI (1) | FI107808B (enExample) |
| RU (1) | RU2247389C2 (enExample) |
| WO (1) | WO2001016356A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2312356C2 (ru) * | 2005-12-28 | 2007-12-10 | Федеральное государственное лечебно-профилактическое учреждение "Научно-клинический центр охраны здоровья шахтеров" Федерального агентства по энергетике РФ | Способ оценки степени тяжести ишемического инсульта у лиц в возрасте до 50 лет |
| RU2413940C2 (ru) * | 2009-02-02 | 2011-03-10 | Государственное образовательное учреждение высшего профессионального образования Воронежская государственная технологическая академия | Способ определения витамина b12 в водных растворах |
| RU2453001C1 (ru) * | 2010-10-18 | 2012-06-10 | Государственное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" | Способ коррекции гипергомоцистеин индуцированного дефицита оксида азота l-норвалином в эксперименте |
| CN114924016B (zh) * | 2022-04-28 | 2024-03-08 | 中国医学科学院北京协和医院 | 同时检测硫酸化及未硫酸化胃泌素g17的方法及其检测试剂盒 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI97304C (fi) * | 1994-11-16 | 1996-11-25 | Locus Genex Oy | Menetelmä mahasyövän riskin seulonnaksi |
-
1999
- 1999-08-31 FI FI991836A patent/FI107808B/fi active
-
2000
- 2000-08-30 CN CNB008122261A patent/CN1158389C/zh not_active Expired - Lifetime
- 2000-08-30 RU RU2002107982/15A patent/RU2247389C2/ru active
- 2000-08-30 WO PCT/FI2000/000733 patent/WO2001016356A1/en not_active Ceased
- 2000-08-30 AU AU68456/00A patent/AU6845600A/en not_active Abandoned
- 2000-08-30 JP JP2001520901A patent/JP2003508059A/ja active Pending
- 2000-08-30 EP EP00956556A patent/EP1210452A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nexø et al. | How to diagnose cobalamin deficiency | |
| JP2579434B2 (ja) | コバラミンおよび葉酸の欠乏を検出および区別する方法 | |
| Werner et al. | Simultaneous determination of neopterin and creatinine in serum with solid-phase extraction and on-line elution liquid chromatography. | |
| JP2014520265A (ja) | 血漿分離デバイス（ｐｓｄ）から得られる血漿中の総ホモシステイン及びメチルマロン酸のｌｃ−ｍｓ／ｍｓによる分析 | |
| Amores-Sánchez et al. | Methods for the determination of plasma total homocysteine: a review | |
| US20110281369A1 (en) | Analysis of mycophenolic acid in saliva using liquid chromatography tandem mass spectrometry | |
| Vernerová et al. | Liquid chromatography method with tandem mass spectrometry and fluorescence detection for determination of inflammatory biomarkers in gingival crevicular fluid as a tool for diagnosis of periodontal disease | |
| Hogeling et al. | Quantification of proteins in whole blood, plasma and DBS, with element-labelled antibody detection by ICP-MS | |
| Chen et al. | A one-step aptasensor for ultrasensitive detection of lung cancer marker homocysteine based on multifunctional carbon nanotubes by square-wave voltammetry | |
| CN100465640C (zh) | 一种高灵敏血浆总同型半胱氨酸测定试剂盒 | |
| CN102967713A (zh) | 同型半胱氨酸检测试剂盒及其制备方法 | |
| JP2003508059A5 (enExample) | ||
| CN114813712A (zh) | 同型半胱氨酸检测试剂盒及同型半胱氨酸的检测方法 | |
| RU2247389C2 (ru) | Способ идентификации индивидуума с риском сосудистого и ракового заболевания | |
| Božič-Mijovski | Hyperhomocysteinemia and thrombophilia | |
| US20180259514A1 (en) | Method to detect blood creatinine and an immunosuppressive drug | |
| Mendis et al. | Association between hyperhomocysteinemia and ischemic heart disease in Sri Lankans | |
| RU2224258C2 (ru) | Способ идентификации индивидуума, у которого существует риск необратимых неврологических повреждений, включающий в себя этапы количественного определения концентрации пепсиногена i (pgi) и витамина в12 | |
| JP2005537022A (ja) | スクリーニングに適応できるホモシステインアッセイ | |
| EP1360499B1 (de) | Bestimmung des zytosolischen nadp-abhängigen malatdecarboxylase-isoenzyms | |
| EP0965043A1 (en) | Detection of cardiac muscle necrosis by immunoassay and appropriate antibodies therefor | |
| Yokoro et al. | Development of an enzyme-linked immunosorbent assay system for the determination of asymmetric dimethylarginine using a specific monoclonal antibody | |
| CN103344768B (zh) | 缺血性心脏病检测试剂盒及其应用 | |
| Tateishi et al. | Stability of bombesin in serum, plasma, urine, and culture media. | |
| CN114910579B (zh) | 血清中脱氧尿苷定量测定方法及在心肌梗死诊断中的应用 |